357 related articles for article (PubMed ID: 30646790)
1. CD19 directed CARs in acute lymphoblastic leukemia: state of the art and beyond.
Quintás-Cardama A
Leuk Lymphoma; 2019 May; 60(5):1346-1348. PubMed ID: 30646790
[No Abstract] [Full Text] [Related]
2. Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells.
Geyer MB; Manjunath SH; Evans AG; Park JH; Davila ML; Cutler CS; Wang X; Wang Y; Senechal B; Rivière I; Sadelain M; Liesveld JL; Brentjens RJ
Leuk Lymphoma; 2018 Jul; 59(7):1717-1721. PubMed ID: 29043880
[No Abstract] [Full Text] [Related]
3. Escape From ALL-CARTaz: Leukemia Immunoediting in the Age of Chimeric Antigen Receptors.
Zheng S; Asnani M; Thomas-Tikhonenko A
Cancer J; 2019; 25(3):217-222. PubMed ID: 31135529
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases.
Zhang J; Yang F; Qiu HY; Wu Q; Kong DQ; Zhou J; Han Y; Wu DP
Leuk Lymphoma; 2019 Jun; 60(6):1454-1461. PubMed ID: 30714847
[TBL] [Abstract][Full Text] [Related]
5. Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia.
Ma F; Ho JY; Du H; Xuan F; Wu X; Wang Q; Wang L; Liu Y; Ba M; Wang Y; Luo J; Li J
Hematol Oncol; 2019 Dec; 37(5):601-608. PubMed ID: 31465532
[TBL] [Abstract][Full Text] [Related]
6. CAR T-cell therapy effective in B acute lymphoblastic leukaemia.
Wang M
Lancet Oncol; 2017 Jun; 18(6):e314. PubMed ID: 28528746
[No Abstract] [Full Text] [Related]
7. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
8. CAR-T cell therapy in paediatric acute lymphoblastic leukaemia - past, present and future.
Rogosic S; Ghorashian S
Br J Haematol; 2020 Nov; 191(4):617-626. PubMed ID: 33190266
[TBL] [Abstract][Full Text] [Related]
9. Strategies for having a more effective and less toxic CAR T-cell therapy for acute lymphoblastic leukemia.
Hashem Boroojerdi M; Rahbarizadeh F; Safarzadeh Kozani P; Kamali E; Safarzadeh Kozani P
Med Oncol; 2020 Oct; 37(11):100. PubMed ID: 33047234
[TBL] [Abstract][Full Text] [Related]
10. Kinetics of immune reconstitution after anti-CD19 chimeric antigen receptor T cell therapy in relapsed or refractory acute lymphoblastic leukemia patients.
Wang Y; Li H; Song X; Qi K; Cheng H; Cao J; Shi M; Yan Z; Jing G; Pan B; Sang W; Wang X; Zhao K; Chen C; Chen W; Zheng J; Li Z; Xu K
Int J Lab Hematol; 2021 Apr; 43(2):250-258. PubMed ID: 33112046
[TBL] [Abstract][Full Text] [Related]
11. Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.
Badar T; Shah NN
Curr Treat Options Oncol; 2020 Feb; 21(2):16. PubMed ID: 32025828
[TBL] [Abstract][Full Text] [Related]
12. Donor origin CAR19 T cell infusion for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation.
Yang X; Dai H; Kang L; Qu C; Li Z; Yin J; Qiu H; Fu C; Han Y; Jin Z; Ma X; Zhu X; Yu L; Wu D; Tang X
Hematol Oncol; 2019 Dec; 37(5):655-658. PubMed ID: 31656047
[No Abstract] [Full Text] [Related]
13. CAR T cells for infection, autoimmunity and allotransplantation.
Maldini CR; Ellis GI; Riley JL
Nat Rev Immunol; 2018 Oct; 18(10):605-616. PubMed ID: 30046149
[TBL] [Abstract][Full Text] [Related]
14. CAR T-cell therapy: Full speed ahead.
Sermer D; Brentjens R
Hematol Oncol; 2019 Jun; 37 Suppl 1():95-100. PubMed ID: 31187533
[TBL] [Abstract][Full Text] [Related]
15. In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.
Ramos CA; Rouce R; Robertson CS; Reyna A; Narala N; Vyas G; Mehta B; Zhang H; Dakhova O; Carrum G; Kamble RT; Gee AP; Mei Z; Wu MF; Liu H; Grilley B; Rooney CM; Heslop HE; Brenner MK; Savoldo B; Dotti G
Mol Ther; 2018 Dec; 26(12):2727-2737. PubMed ID: 30309819
[TBL] [Abstract][Full Text] [Related]
16. How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy.
Aldoss I; Forman SJ
Blood; 2020 Mar; 135(11):804-813. PubMed ID: 31899793
[TBL] [Abstract][Full Text] [Related]
17. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia.
Orlando EJ; Han X; Tribouley C; Wood PA; Leary RJ; Riester M; Levine JE; Qayed M; Grupp SA; Boyer M; De Moerloose B; Nemecek ER; Bittencourt H; Hiramatsu H; Buechner J; Davies SM; Verneris MR; Nguyen K; Brogdon JL; Bitter H; Morrissey M; Pierog P; Pantano S; Engelman JA; Winckler W
Nat Med; 2018 Oct; 24(10):1504-1506. PubMed ID: 30275569
[TBL] [Abstract][Full Text] [Related]
18. CAR-T Cell Therapy.
Ahmad A
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560285
[TBL] [Abstract][Full Text] [Related]
19. Immunophenotypic changes in leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia after treatment with CD19-directed chimeric antigen receptor (CAR)- expressing T cells.
Mikhailova E; Illarionova O; Shelikhova L; Zerkalenkova E; Molostova O; Olshanskaya Y; Novichkova G; Maschan A; Maschan M; Popov A
Haematologica; 2022 Apr; 107(4):970-974. PubMed ID: 34911282
[No Abstract] [Full Text] [Related]
20. TanCAR T cells targeting CD19 and CD133 efficiently eliminate MLL leukemic cells.
Li D; Hu Y; Jin Z; Zhai Y; Tan Y; Sun Y; Zhu S; Zhao C; Chen B; Zhu J; Chen Z; Chen S; Li J; Liu H
Leukemia; 2018 Sep; 32(9):2012-2016. PubMed ID: 30046161
[No Abstract] [Full Text] [Related]
[Next] [New Search]